Evidence map›Paper›PMID 38229875›Full record

ArticleNeurology. Clinical practice2024

Characterization of Fatigue in Primary Mitochondrial Myopathies: Findings From a Qualitative Interview Study.

Amel Karaa, Nathan Johnson, Ian Clarkson, Wendy Newman, Alejandro Dorenbaum, Bruce H Cohen

Open access · hybridAbstract read
In one paragraph

Article in Neurology. Clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Myopathies in clinical care: a focus on treatable causes.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Amel KaraaDivision of Genetics (AK), Massachusetts General Hospital, Pediatric Department, Harvard Medical School; Endpoint Outcomes (NJ, IC), Boston, MA; Reneo Pharmaceuticals, Inc (WN, AD), San Diego, CA; and Akron Children's Hospital (BHC), Department of Pediatrics and Integrative Medical Sciences, Northeast Ohio Medical University.ORCID https://orcid.org/0000-0001-5781-9824
Nathan JohnsonDivision of Genetics (AK), Massachusetts General Hospital, Pediatric Department, Harvard Medical School; Endpoint Outcomes (NJ, IC), Boston, MA; Reneo Pharmaceuticals, Inc (WN, AD), San Diego, CA; and Akron Children's Hospital (BHC), Department of Pediatrics and Integrative Medical Sciences, Northeast Ohio Medical University.ORCID https://orcid.org/0000-0002-7303-6587
Ian ClarksonDivision of Genetics (AK), Massachusetts General Hospital, Pediatric Department, Harvard Medical School; Endpoint Outcomes (NJ, IC), Boston, MA; Reneo Pharmaceuticals, Inc (WN, AD), San Diego, CA; and Akron Children's Hospital (BHC), Department of Pediatrics and Integrative Medical Sciences, Northeast Ohio Medical University.ORCID https://orcid.org/0000-0002-5438-8886
Wendy NewmanDivision of Genetics (AK), Massachusetts General Hospital, Pediatric Department, Harvard Medical School; Endpoint Outcomes (NJ, IC), Boston, MA; Reneo Pharmaceuticals, Inc (WN, AD), San Diego, CA; and Akron Children's Hospital (BHC), Department of Pediatrics and Integrative Medical Sciences, Northeast Ohio Medical University.ORCID https://orcid.org/0009-0008-2510-2253
Alejandro DorenbaumDivision of Genetics (AK), Massachusetts General Hospital, Pediatric Department, Harvard Medical School; Endpoint Outcomes (NJ, IC), Boston, MA; Reneo Pharmaceuticals, Inc (WN, AD), San Diego, CA; and Akron Children's Hospital (BHC), Department of Pediatrics and Integrative Medical Sciences, Northeast Ohio Medical University.ORCID https://orcid.org/0000-0001-9641-9444
Bruce H CohenDivision of Genetics (AK), Massachusetts General Hospital, Pediatric Department, Harvard Medical School; Endpoint Outcomes (NJ, IC), Boston, MA; Reneo Pharmaceuticals, Inc (WN, AD), San Diego, CA; and Akron Children's Hospital (BHC), Department of Pediatrics and Integrative Medical Sciences, Northeast Ohio Medical University.ORCID https://orcid.org/0000-0003-2253-8955
Harvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Primary mitochondrial myopathies are genetic disorders that primarily affect peripheral skeletal muscles. Patients with primary mitochondrial myopathies often experience muscle weakness, fatigue, and other significant impacts on health-related quality of life. The aim of this noninterventional qualitative study was to collect the most bothersome fatigue-related symptoms and impacts reported by patients with primary mitochondrial myopathies and determine whether the questions included in an existing patient-reported outcome measure, the Modified Fatigue Impact Scale, are relevant and interpretable for this population. Methods: The interviews contained a concept elicitation exercise to understand the most bothersome primary mitochondrial myopathies symptoms and impacts and a cognitive debriefing section to review the questions included in the Modified Fatigue Impact Scale for relevance and interpretability. Transcripts were coded using ATLAS.ti software. Results: Interviews were conducted with 16 patients who were aged 16 years and older with a genetically confirmed and clinical diagnosis of symptomatic primary mitochondrial myopathies. Concept elicitation interviews established that while patients with mitochondrial myopathies reported a wide variety of symptoms and impacts, one of the most impactful symptoms discussed was fatigue. Cognitive debriefing interview results confirmed that the Modified Fatigue Impact Scale items were relevant, were interpretable, and largely captured patients' experience with fatigue. Discussion: Fatigue was one of the most widely discussed experiences discussed by participants and was considered the most important symptom/impact to treat by most of the participants. The Modified Fatigue Impact Scale could be used in future clinical trials to measure treatment benefit in fatigue-related impacts.

Identifiers

PMID38229875
PMCPMC10790285
OpenAlexW4390122758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.